{"title":"阿立哌唑可以持续抑制慢性抽动障碍和抽动秽语障碍的症状:一个病例系列","authors":"S. Taşkıran, A. Tufan, B. Semerci","doi":"10.5455/BCP.20160220032354","DOIUrl":null,"url":null,"abstract":"ABSTRACTTic disorders may cause impairment both by themselves and associated comorbidities. Medications for tic disorders are indicated when tics are moderate/severe causing severe impairment and in presence of comorbid disorders responsive to medications. Duration of improvement is still not known as the literature lacks prospective studies with a long follow-up period. This case series aims to report management of tic disorders with aripiprazole in patients with different ages. Here, we describe 8 cases with complex motor tic disorder or Tourette's Disorder in which aripiprazole was used. The ages of patients were varied, from 9 to 57 years. Mean follow-up was 19.6 weeks. Mean dose of aripiprazole for pediatric patients was 15.4 mg/ day while it was 12.5 mg/ day for adult patients. All patients benefited from treatment with aripiprazole in the long term. Our results should be supported with controlled studies.","PeriodicalId":17852,"journal":{"name":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Aripiprazole can a Viable Choice for Persistant Suppression of Symptoms in Managing Chronic Tic Disorders and Tourette's Disorder Through the Life Span: A Case Series\",\"authors\":\"S. Taşkıran, A. Tufan, B. Semerci\",\"doi\":\"10.5455/BCP.20160220032354\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"ABSTRACTTic disorders may cause impairment both by themselves and associated comorbidities. Medications for tic disorders are indicated when tics are moderate/severe causing severe impairment and in presence of comorbid disorders responsive to medications. Duration of improvement is still not known as the literature lacks prospective studies with a long follow-up period. This case series aims to report management of tic disorders with aripiprazole in patients with different ages. Here, we describe 8 cases with complex motor tic disorder or Tourette's Disorder in which aripiprazole was used. The ages of patients were varied, from 9 to 57 years. Mean follow-up was 19.6 weeks. Mean dose of aripiprazole for pediatric patients was 15.4 mg/ day while it was 12.5 mg/ day for adult patients. All patients benefited from treatment with aripiprazole in the long term. Our results should be supported with controlled studies.\",\"PeriodicalId\":17852,\"journal\":{\"name\":\"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-11-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5455/BCP.20160220032354\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klinik Psikofarmakoloji Bulteni-bulletin of Clinical Psychopharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5455/BCP.20160220032354","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q","JCRName":"Medicine","Score":null,"Total":0}
Aripiprazole can a Viable Choice for Persistant Suppression of Symptoms in Managing Chronic Tic Disorders and Tourette's Disorder Through the Life Span: A Case Series
ABSTRACTTic disorders may cause impairment both by themselves and associated comorbidities. Medications for tic disorders are indicated when tics are moderate/severe causing severe impairment and in presence of comorbid disorders responsive to medications. Duration of improvement is still not known as the literature lacks prospective studies with a long follow-up period. This case series aims to report management of tic disorders with aripiprazole in patients with different ages. Here, we describe 8 cases with complex motor tic disorder or Tourette's Disorder in which aripiprazole was used. The ages of patients were varied, from 9 to 57 years. Mean follow-up was 19.6 weeks. Mean dose of aripiprazole for pediatric patients was 15.4 mg/ day while it was 12.5 mg/ day for adult patients. All patients benefited from treatment with aripiprazole in the long term. Our results should be supported with controlled studies.